Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2

Conditions

Carcinoma, Non-Small-Cell Lung 42Breast Neoplasms 28Parkinson Disease 4, Autosomal Dominant Lewy Body 23Neoplasms 22Multiple Myeloma 18Leukemia, Myeloid, Acute 14Neoplasm Metastasis 11Carcinoma, Renal Cell 10Leukemia 10Melanoma 10Ovarian Neoplasms 10Recurrence 10Leukemia, Lymphocytic, Chronic, B-Cell 9Precursor Cell Lymphoblastic Leukemia-Lymphoma 9Adenocarcinoma 8Carcinoma, Hepatocellular 8Colorectal Neoplasms 8Leukemia, Myelogenous, Chronic, BCR-ABL Positive 8Lung Neoplasms 8Myelodysplastic Syndromes 8Prostatic Neoplasms 8Stomach Neoplasms 8Lymphoma, Follicular 7Bronchiolitis Obliterans Syndrome 6Carcinoma 6Lymphoma 6Lymphoma, Non-Hodgkin 6Small Cell Lung Carcinoma 6Urinary Bladder Neoplasms 6Cholangiocarcinoma 5

Interventions

pembrolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Has announcements × Carcinoma, Merkel Cell × Clear all
NCT03599713 2025-08-05

A Study of INCMGA00012 in Metastatic Merkel Cell Carcinoma (POD1UM-201)

Incyte Corporation

Phase 2 Completed
107 enrolled 16 charts 1 FDA
Dermatologic

Carcinoma, Merkel Cell

NCT02267603 2023-07-05

Pembrolizumab in Treating Patients With Advanced Merkel Cell Cancer

National Cancer Institute (NCI)

Phase 2 Completed
50 enrolled 11 charts 1 FDA
Dermatologic

Carcinoma, Merkel Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡